跳至主要内容
临床试验/NCT03201549
NCT03201549已完成不适用

The Effects of Increased Fructose Ingestion on FGF-21 Levels in Humans

Beth Israel Deaconess Medical Center2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2017年7月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
20
试验地点
2
主要终点
Change in serum FGF21 levels

研究概览

简要总结

The primary aim of this study is to examine the effect of fructose ingestion on serum FGF-21 levels in humans.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Ages 18-60
  • BMI 19-25 kg/m2; 19-23 for Asian subjects
  • Stable weight (variation < 3 kg within 6 months of screening visit)
  • Ability to give informed consent in English
  • Use of medically approved form of contraception

排除标准

  • Fasting blood glucose >100
  • Hemoglobin A1C% > 6.5%
  • Fasting triglycerides >150
  • Type 1 or type 2 diabetes mellitus diagnosed according to American Diabetes Association criteria
  • Coronary heart disease (history of myocardial infarction, unstable angina pectoris, or congestive heart failure)
  • Uncontrolled hypertension (BP > 160/100 mmHg on or off antihypertensive medication) intravenous drug use
  • Recent weight loss (> 3 kg within 6 months of the screening visit)
  • Gastroparesis
  • Inflammatory or irritable bowel disease
  • Malignancy treated with chemotherapy within the past 3 years
  • Depression or psychosis requiring hospitalization
  • Renal insufficiency (creatinine clearance < 40 ml/min)
  • Transaminases > 2x above the normal range
  • Known liver disease
  • Pregnancy within 6 months of the screening visit
  • Lactation
  • Failure to use medically approved contraceptive methods
  • History of surgery for the treatment of obesity (gastric banding, gastric bypass, gastric stapling)
  • Change in dose of thyroid hormone or antithyroidal medication within 3 months of screening visit
  • History of alcohol abuse within the past 5 years
  • Fructose intolerance
  • Exclusionary medications:
  • Oral steroids
  • Metformin
  • Weight loss medications including nonprescription supplements

结局指标

主要结局

Change in serum FGF21 levels

时间窗: 2 weeks

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jody Dushay

Assistant Professor of Medicine

Beth Israel Deaconess Medical Center

研究点 (2)

Loading locations...

相似试验